What is BCAX's current stock price?

BCAX (Bicara Therapeutics Inc. Common Stock) is currently trading at $21.68 with a market cap of $1.19B.

What sector is Bicara Therapeutics Inc. Common Stock in?

Bicara Therapeutics Inc. Common Stock (BCAX) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is BCAX a good stock to buy?

Analysts have a Buy consensus on BCAX with a price target of $28.60. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

BCAX Bicara Therapeutics Inc. Common Stock

Healthcare

$21.68+4.03%ClosedMarket Cap: $1.19B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.56

P/S

0.00

EV/EBITDA

-5.10

DCF Value

$1.64

FCF Yield

-9.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-35.9%

ROA

-28.4%

ROIC

-33.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-56.2M	$—
Q4 null	$0.00	$-37.4M	$—
FY null	$0.00	$-137.9M	$—
Q3 null	$0.00	$-36.3M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$28.60

Target (Median)

$28.00

Target Range

$18.00 - $42.00

3 Strong Buy9 Buy3 Hold0 Sell0 Strong Sell

Goldman SachsNeutral

2026-05-12

Morgan StanleyOverweight

2026-05-12

WedbushOutperform

2026-03-31

CitizensMarket Outperform

2026-03-31

HC Wainwright & Co.Buy

2026-03-31

Trading Activity

Insider Trades

View All

Mazumdar Clairedirector, officer: Chief Executive Officer

SellWed May 20

Mazumdar Clairedirector, officer: Chief Executive Officer

SellWed May 20

Mazumdar Clairedirector, officer: Chief Executive Officer

SellWed May 20

Cohlhepp Ryandirector, officer: President and COO

SellMon May 18

Cohlhepp Ryandirector, officer: President and COO

SellMon May 18

Latest News

Bicara Therapeutics CEO Quietly Sold Shares. Her 339,000-Share Stake Speaks Louder.The Motley Fool · Thu Mar 26

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

-0.56

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.

Peers